newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

  • Serina Therapeutics enrolled its first patient in the global Phase 1b registrational trial for SER-252 in Australia.
  • The trial evaluates the safety, tolerability, pharmacokinetics, & preliminary efficacy of SER-252 in patients with advanced Parkinson's disease.
  • Serina maintains an operational presence in Australia to support efficient enrollment in Cohort 1.
  • The company remains on track to initiate first patient dosing during the first quarter of 2026.
  • SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation using the proprietary POZ Platform.
  • Serina has aligned with the FDA on a registrational development strategy under a 505(b)(2) NDA pathway.
  • Partnerships with Parkinson's Australia & Neuroscience Trials Australia are in place to support patient identification & enrollment.
  • SER-252 aims to reduce levodopa-related motor complications without causing skin reactions.